ADCs, bi-specific antibodies, pan-HER inhibitors, allosteric EGFR inhibitors and other tailored treatments have recently enriched the therapeutic arsenal against EGFR mutant NSCLC with intrinsic or acquired resistance to EGFR-TKIs. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.